Učitavanje...
Delay of treatment change following objective progression on first-line erlotinib in EGFR-mutant lung cancer
BACKGROUND: Erlotinib is a highly active EGFR kinase inhibitor approved for first-line use in lung cancers harboring EGFR mutations. Anecdotal experience suggests this drug may provide continued disease control following objective progression of disease (PD), however this has not been systematically...
Spremljeno u:
| Izdano u: | Cancer |
|---|---|
| Glavni autori: | , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2015
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4525718/ https://ncbi.nlm.nih.gov/pubmed/25876525 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29397 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|